When the FDA made the decision to give Johnson & Johnson’s diabetes drug Invokana a black box warning in 2017, one would like to believe that the decision was not made lightly. The boxed warning is the strongest warning the agency can issue for a drug on the US healthcare market and indicates that the product can pose grave risks to the consumer if used. There is ...
Patients taking Invokana and other SGLT2 inhibitors to treat and control their Type II diabetes have done so with the risk of a wide variety of adverse side effects for quite some time. The drugs’ links to serious conditions like bone fractures, kidney failure, and a particularly dangerous condition known as ketoacidosis are well established. They can strike anyone – young, old, men, and women.
However, there is read more.... --> continue reading...
Known as SGLT2 inhibitors for short, sodium glucose co-transporter 2 inhibitors are a class of drugs intended for certain individuals with Type II diabetes. The drugs prevent glucose from being absorbed in the kidneys and reduce glucose in the blood by causing it to be expelled in the urine.
Unfortunately, this relatively new class of drugs has already allegedly caused enough ...
continue reading...Woman Claims Invokana Caused Her Diabetic Ketoacidosis
Posted December 6, 2015 in Product News and Recalls
A Georgia woman has filed an Invokana ketoacidosis lawsuit claiming Janssen Pharmaceutical’s drug caused her to develop the potentially life-threatening blood condition known as diabetic ketoacidosis.
Invokana (canagliflozin) is one of a new line of diabetes medications called sodium-glucose cotransport-2 (SLGT2) inhibitors. Unlike traditional insulin treatments, SGLT2 inhibitors regulate the body’s blood sugar levels by reabsorbing excess glucose in the kidneys and disposing of it through urine. Less than two years after Invokana, Farxiga, and Jardiance ...
continue reading...Invokana Class-Action Lawsuit Filed in Canada
Posted November 1, 2015 in Product News and Recalls
The diabetes drug Invokana has become the focus of a national class-action lawsuit in Canada, CBC Nova Scotia reports. According to a statement filed in the Ontario Supreme Court of Justice, the lead plaintiff alleges that Janssen Pharmaceuticals’ new sodium-glucose cotransporter-2 (SGLT2) inhibitor was responsible for her kidney failure.
SGLT2 inhibitors, a new line of type 2 diabetes medications, work by directing excess blood sugars to be eliminated through urine. But not long after they reached the ...
continue reading...Case Report Highlights Diabetic Ketoacidosis Risk with SGLT2 Inhibitors
Posted October 16, 2015 in Product News and Recalls
Another case report links sodium-glucose co-transporter 2 (SGLT2) inhibitors like Invokana to diabetic ketoacidosis, a severe and potentially fatal condition wherein the body produces too many blood acids. The article, published in the journal Practical Diabetes, presents the case of a 58-year-old woman who suffered severe diabetic ketoacidosis after her twice-daily insulin regimen was replaced by dapagliflozin.
SGLT2 inhibitors, the new class of type 2 diabetes medication introduce in 2013, were first linked to ...
continue reading...
